Keck P E, Pope H G, Cohen B M, McElroy S L, Nierenberg A A
Biological Psychiatry Laboratory, Mailman Research Center, McLean Hospital, Belmont, Mass.
Arch Gen Psychiatry. 1989 Oct;46(10):914-8. doi: 10.1001/archpsyc.1989.01810100056011.
A number of risk factors have been proposed for the development of neuroleptic malignant syndrome, but these have not been subjected to controlled study. To address this problem, we performed a case-control study comparing 18 patients with neuroleptic malignant syndrome and 36 matched neuroleptic-treated control patients with no known history of the syndrome to identify potential risk factors. Patients with neuroleptic malignant syndrome displayed significantly greater psychomotor agitation, received significantly higher doses of neuroleptics at greater rates of dosage increase, and received a greater number of intramuscular injections than controls.
对于抗精神病药物恶性综合征的发病，已经提出了一些风险因素，但这些因素尚未经过对照研究。为了解决这个问题，我们进行了一项病例对照研究，比较了18例抗精神病药物恶性综合征患者和36例匹配的接受抗精神病药物治疗且无该综合征已知病史的对照患者，以确定潜在的风险因素。与对照组相比，抗精神病药物恶性综合征患者表现出明显更强的精神运动性激越，接受的抗精神病药物剂量明显更高，剂量增加率也更高，且接受的肌肉注射次数更多。
Zotero 插件